TMOD2

Across TCGA pan-cancer cohorts, TMOD2 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated TMOD2 data layer compared with 26 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher TMOD2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TMOD2 expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.

KIRC, LUAD, and LGG are the cancer types where TMOD2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRC	OS	Median	All	0.181	0.805	.002	21	view →
LUAD	OS	Median	III,IV	0.163	0.663	.012	12	view →
LGG	DFS	Median	All	0.080	0.826	<.001	6	view →
GBM	DFS	Median	All	1.000	0.192	.036	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

TMOD2–KIRC (OS)

Open the KIRC breakdown →